Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd. Fundamental Analysis
Sumitomo Pharma Co., Ltd. (SMDPY) shows strong financial fundamentals with a PE ratio of 8.51, profit margin of 24.42%, and ROE of 49.42%. The company generates $457.6B in annual revenue with strong year-over-year growth of 26.79%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 88.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze SMDPY's fundamental strength across five key dimensions:
Efficiency Score
ExcellentSMDPY demonstrates superior asset utilization.
Valuation Score
ExcellentSMDPY trades at attractive valuation levels.
Growth Score
ModerateSMDPY shows steady but slowing expansion.
Financial Health Score
ExcellentSMDPY maintains a strong and stable balance sheet.
Profitability Score
ExcellentSMDPY achieves industry-leading margins.
Key Financial Metrics
Is SMDPY Expensive or Cheap?
P/E Ratio
SMDPY trades at 8.51 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SMDPY's PEG of -0.00 indicates potential undervaluation.
Price to Book
The market values Sumitomo Pharma Co., Ltd. at 3.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 5.39 times EBITDA. This is generally considered low.
How Well Does SMDPY Make Money?
Net Profit Margin
For every $100 in sales, Sumitomo Pharma Co., Ltd. keeps $24.42 as profit after all expenses.
Operating Margin
Core operations generate 15.68 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $49.42 in profit for every $100 of shareholder equity.
ROA
Sumitomo Pharma Co., Ltd. generates $13.70 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Sumitomo Pharma Co., Ltd. produces operating cash flow of $55.26B, showing steady but balanced cash generation.
Free Cash Flow
Sumitomo Pharma Co., Ltd. generates strong free cash flow of $48.82B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $122.89 in free cash annually.
FCF Yield
SMDPY converts 5.13% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
8.51
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.29
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.08
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.90
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.40
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.49
vs 25 benchmark
ROA
Return on assets percentage
0.14
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How SMDPY Stacks Against Its Sector Peers
| Metric | SMDPY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 8.51 | 29.78 | Better (Cheaper) |
| ROE | 49.42% | 792.00% | Weak |
| Net Margin | 24.42% | -23280.00% (disorted) | Strong |
| Debt/Equity | 0.90 | 0.25 | Weak (High Leverage) |
| Current Ratio | 1.40 | 4.60 | Neutral |
| ROA | 13.70% | -18077.00% (disorted) | Strong |
SMDPY outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Sumitomo Pharma Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-17.38%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-42.01%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-64.23%
Industry Style: Defensive, Growth, Innovation
Declining